United States & Novartis
20 shared events · Importance 5 · Last updated Sep 22, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
International
United States: The United States is receiving significant investment from Swiss companies, which will boost its economy and create jobs, though it also imposed new tariffs related to forced labor.
Novartis: Novartis is a key investor, announcing two U.S. projects: a biomedical research center in San Diego and a cancer-drug production facility in Texas.
Jun 07, 2026 · 7 articles
Business
United States: The US is part of North America, which held the largest market share in 2025, supported by strong regulatory frameworks and advanced manufacturing.
Novartis: Novartis is a key player in the antibody therapeutics market, benefiting from the projected market growth.
Jul 28, 2026 · 6 articles
Regulatory
United States: The United States is noted as a jurisdiction where Novartis lost a bid to block a generic version of Sacubitril/valsartan, representing a contrasting legal outcome.
Novartis: Novartis is the patent holder and beneficiary of the court ruling, which protects its blockbuster drug Sacubitril/valsartan from generic competition in the UK, supporting its revenue and market position.
Aug 13, 2026 · 6 articles
Regulatory
United States: Cited as a key competitor attracting far more pharmaceutical investment, with healthcare spending at about 2% of GDP versus Europe's 1%. Its more aggressive policies are said to be drawing capital and launches away from Europe.
Novartis: A signatory of the open letter urging the European Union and member states to strengthen the region's pharmaceutical industry. The appeal is aimed at improving the investment and regulatory climate it operates in.
Sep 22, 2026 · 6 articles
Business
United States: The United States is home to Bristol Myers and health authorities involved in the review.
Novartis: Novartis paused eight Rap cell trials after three patient deaths, triggering a safety review. Despite this, shares rose 4% on positive Remibrutinib data.
Sep 01, 2026 · 7 articles
Business
United States: Home country of Pfizer entities involved in the transaction.
Novartis: Acquirer of Minipress trademarks, expanding its cardiovascular portfolio; shares rose 2.9% on the announcement.
Sep 07, 2026 · 6 articles
Regulatory
United States: The U.S. FDA granted approval, impacting the domestic IgAN patient population of about 160,000.
Novartis: Novartis' Fabhalta and Vanrafia are among the competitors to TRUTAKNA in IgAN.
Jul 07, 2026 · 6 articles
Business
United States: The US is relevant as the key market for Novartis' pipeline, the location of affected peers Dyne and Sarepta, and the jurisdiction of the FDA decisions on the remaining AOC therapies.
Novartis: Novartis is the central entity of the event; the del-desiran Phase III failure and prior pelacarsen setback erased roughly $30 billion in market value and intensified investor scrutiny of its M&A strategy and pipeline.
Sep 08, 2026 · 21 articles
Business
United States: Key market where FDA approvals and Nasdaq-listed ADRs for the share consideration shape the deal's milestone structure and investor access.
Novartis: Dominant radiopharmaceutical player with Pluvicto and Lutathera faces a more vertically integrated competitor as Telix absorbs ITM's isotope supply and neuroendocrine tumor pipeline.
Sep 21, 2026 · 6 articles
Business
United States: Home country of Avidity Biosciences and Artisan Partners Asset Management, both central to the acquisition and activist campaign.
Novartis: Central subject of the event; its shares suffered a record fall after back-to-back trial setbacks and it now faces public shareholder pressure for board and governance changes.
Sep 10, 2026 · 6 articles
Business
United States: The US is a key market for PentixaFor, with an expanded patient pool due to new screening guidelines.
Novartis: Novartis reported strong Pluvicto sales growth, indicating a booming radiopharma market that could benefit PentixaFor's launch.
Jul 15, 2026 · 10 articles
Domestic
United States: Prospects of a peace deal between Iran>>> and the United States>>> influenced investor sentiment, contributing to the positive mood in the Switzerland>>> market.
Novartis: Novartis>>> shed 0.3%-0.7% in one session but moved up by 1.85% in another, showing mixed performance in the Switzerland>>> market.
May 21, 2026 · 8 articles
Business
United States: The United States is the regulatory and market jurisdiction for the IPO, with the SEC and Nasdaq based there.
Novartis: Novartis' Leqvio is another competitor in the PCSK9 inhibitor market. Scribe's progress may affect Novartis's competitive position.
Jul 06, 2026 · 25 articles
Business
United States: The United States is the primary market for Lantheus' products and the regulatory jurisdiction for the deal, with potential antitrust review.
Novartis: Novartis is mentioned as the maker of Pluvicto, a competitor to a Lantheus-Eli Lilly therapeutic that was abandoned.
Aug 03, 2026 · 7 articles
Business
United States: Country where Palsonify is approved and where most patients reside.
Novartis: Competitor in acromegaly market.
Jul 06, 2026 · 34 articles
Regulatory
Novartis: Novartis is among the pharmaceutical companies that agreed to lower drug prices for United States — Medicaid and cash payers as part of the deals with the Donald Trump administration.
Dec 19, 2025 · 7 articles
Business
Novartis: Novartis settled a lawsuit with the estate of Henrietta Lacks over the unauthorized use of her cells, which were used to develop various medical advancements. This settlement resolves a significant legal and ethical challenge for Novartis.
Feb 26, 2026 · 7 articles
International
Novartis: Novartis employed Jason Thomas, a pharmaceutical researcher who was found dead after disappearing, adding a pharmaceutical link to the broader pattern of mysterious deaths.
Apr 11, 2026 · 6 articles
Business
Novartis: Novartis announced the expansion of its community health programs to address gaps in heart disease and cancer care globally, which could positively impact its public image and long-term market position.
Apr 09, 2026 · 7 articles
ERGEN INTELLIGENCE
Explore this relationship live
Track how United States and Novartis interact across events, view sentiment trends, and discover connected entities.
Open Dashboard